Alzheimer’s Therapeutics Market By Drug Type 2016-2022 | Size, Share and Forecast | Credence Research
Jul 10, 2019
Alzheimer's therapeutics market is anticipated to reach USD 14,856.3 million by 2022, expanding at a CAGR of 8.02% from 2016 to 2022.
SANJOSE, United States - July 10, 2019 /MarketersMedia/ —
The latest market report issued by Credence Research, Inc. "Global Alzheimer's Therapeutics Market–Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016–2022," Alzheimer's therapeutics market was estimated at USD 8,524.9 million in 2015 and is anticipated to reach USD 14,856.3 million by 2022, expanding at a CAGR of 8.02% from 2016 to 2022.
Alzheimer's disease is a progressive, and currently, incurable disease and potential or supportive treatments have only emerged in the last decade. However, there is a lack of efficacy or target-specificity in the treatments currently available. There are two types of classes of drugs used in Alzheimer's disease treatment, acetylcholinesterase (ACE) inhibitors, and N-methyl-D-aspartate (NMDA) receptor antagonist. ACE inhibitors constitute of galantamine hydrochloride, donepezil hydrochloride and rivastigmine; NMDA receptor antagonist includes mematidine hydrochloride. Since the discovery of what plaques and tangles included in Alzheimer's amyloid β (Aβ) peptide and hyperphosphorylated tau (p-tau) protein, respectively. Immense research and development have been conducted to develop therapeutics that can limit synthesis rates, reduce toxicity, or clear these factors from the brain. These attempts, however, were mostly unsuccessful. Hence, considering the continuously rising Alzheimer prevalent population, as well as limited drugs available for treatment, Alzheimer’s disease presents a lucrative opportunity for an effective disease-modifying therapy to enter the market.
The phase III drugs included in the pipeline analysis are ENA713 (Novartis Pharmaceuticals), Flutemetamol (18F) (GE Healthcare), LY450139 (Eli Lilly and Company), Dimebon (Medivation, Inc. & Pfizer, Inc.), and Aripiprazole/ BMS-337039 (Otsuka Pharmaceutical, Inc.). Small molecule drugs still dominate the overall pipeline for Alzheimer. However, the pipeline still contains a considerable number of biologics with a total of 86 molecules, represented throughout all development stages. The diversity of the various molecule types in the biological group, according to market experts, shows a certain level of innovation, with new avenues being explored in recent failure accounts. Overall, late-stage clinical trials have highlighted very few molecules that during the forecast period, could potentially replace current treatments.
Key Market Movements:
Market experts suggest that a family history of Alzheimer’s increases the risk of disease development by 7.5 times
The incidence and prevalence of Alzheimer’s disease doubles every five years after age 65 years
Currently, the population of developed countries is at high risk of Alzheimer due to increasing geriatric population
In developing countries from the Asia Pacific and Latin America, the awareness related to age-specific diseases such as dementia or Alzheimer is increasing
Get Sample: https://www.credenceresearch.com/sample-request/57811
According to Alzheimer’s Society, there are no drug treatments that can cure Alzheimer's disease or any other common type of dementia. However, medicines have been developed for Alzheimer's disease that can temporarily alleviate symptoms, or slow down their progression, in some cases. There are two types of drug classes used in treatment of Alzheimer’s disease, acetylcholinesterase (ACE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonist.
By Drug types:
the Alzheimer’s therapeutics market is segmented into:
Memantine Hydrochloride
Donepezil Hydrochloride
Rivastigmine
Galantamine Hydrobromide
Pipeline Analysis
According to Alzheimer’s Society, there are no drug treatments that can cure Alzheimer's disease or any other common type of dementia. However, medicines have been developed for Alzheimer's disease that can temporarily alleviate symptoms, or slow down their progression, in some cases. There are two types of drug classes used in treatment of Alzheimer’s disease, acetylcholinesterase (ACE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonist. Based on the drug type, the Alzheimer’s therapeutics market is segmented into:
Phase III Drugs:
ENA713 (Novartis Pharmaceuticals)
Flutemetamol (18F) (GE Healthcare)
LY450139 (Eli Lilly and Company)
Dimebon (Medivation, Inc. & Pfizer, Inc.)
Aripiprazole (BMS-337039) (Otsuka Pharmaceutical, Inc.)
Phase II Drugs:
florbetapir 18F (Avid Radiopharmaceuticals)
MK0249 (Merck Sharp & Dohme Corp.)
Biological: ACC-001 3 μg (Pfizer, Inc.)
Biological: ACC-001 10 μg (Pfizer, Inc.)
Biological: ACC-001 + QS-21 (Pfizer, Inc.)
ELND005 (Scyllo-inositol) (Transition Therapeutics Ireland Limited)
EGb761 (Ipsen)
CHF 5074 (CERESPIR)
Phase I Drugs:
Biological: V950 (Merck Sharp & Dohme Corp.)
Browse the full report Alzheimer’s Therapeutics Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 at https://www.credenceresearch.com/report/alzeimers-therapeutic-market
ToC:
Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
Chapter 2 Executive Summary
2.1 Global Alzheimer’s Therapeutics Market Portaiture
2.2 Global Alzheimer’s Therapeutics Treament Market, by Drugs, 2015 (USD Mn)
2.3 Relativity Analysis: Global Alzheimer’s Therapeutics Market, by Geography, 2015 & 2022 (USD Mn)
Chapter 3 Alzheimer’s Therapeutics Market: Market Dynamics and Outlook
3.1 Alzheimer’s Therapeutics Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Alzheimer’s Therapeutics Market, 2015 (Value %)
Chapter 4 Global Alzheimer’s Therapeutics Market, By Drugs
4.1 Preface
4.2 Memantine Hydrochloride
4.3 Donepezil Hydrochloride
4.4 Rivastigmine
4.5 Galantamine Hydrobromide
4.6 Pipeline Analysis
4.6.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.6.1.1 ENA713
4.6.1.2 Flutemetamol (18F)
4.6.1.3 LY450139
4.6.1.4 Dimebon
4.6.1.5 Aripiprazole/ BMS-337039
4.6.2 Tabular Representation of Phase II and I Drugs
Chapter 5 Global Alzheimer’s Therapeutics Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Rest of the World (RoW)
5.5.1 Latin America
5.5.2 Middle East and Africa
Chapter 6 Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Novartis International AG
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Axovant Sciences Ltd.
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
6.3.4 News Coverage
6.4 Acadia Pharmaceuticals, Inc.
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 Biotie Therapies
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Astra Zeneca plc
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product portfolio
6.6.4 News Coverage
6.7 Eli Lilly, Inc.
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 F. Hoffman Le Roche
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
6.9 Merck & Co.
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 H. Lundbeck A/S
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage
6.11 Takeda Pharmaceutical Company Ltd.
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage
Browse the full report Alzheimer’s Therapeutics Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 at https://www.credenceresearch.com/report/alzeimers-therapeutic-market
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.
Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research
Address: 105 N 1st ST #429, SAN JOSE,, CA 95103, United States
Phone: 18003618290
Website: https://www.credenceresearch.com
Source: MarketersMedia
Release ID: 88894959
More News
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.